- Case report
- Open Access
Idiopathic pulmonary fibrosis and coronary artery disease
© Cicchitto et al.; licensee BioMed Central Ltd. 2014
- Received: 17 April 2014
- Accepted: 7 May 2014
- Published: 30 May 2014
Idiopathic pulmonary fibrosis (IPF) is defined as a chronic fibrosing interstitial disease of unknown cause, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP); it generally progresses into respiratory failure and death. Although progression of the disease is the most common cause of death, there are increasing reports of its association with other pathologies has been reported: e.g., IPF patients seem more susceptible to cardiovascular diseases. Therefore, other pathologies might also influence the natural course.
In this paper, we describe a case of IPF and coronary artery disease (CAD). We emphasize the importance of cardiopulmonary exercise test (CPET) as a useful procedure to monitor disease progression in IPF patients. We also stress the importance of a careful analysis of variables measured for an accurate interpretation of the clinical picture and an improvement of the clinical management of patients. Moreover, we suggest that a careful assessment of CPET parameters may additionally help in the early detection of high cardiovascular ischemic risk.
- Cardiopulmonary exercise test
- Coronary artery disease
- Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is defined as a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) . People with IPF usually die because of progression of their underlying lung disease , even if there is evidence of increased incidence of other diseases, such as lung cancer [3, 4], which could affect the time of death. Furthermore, IPF patients seem more susceptible to developing coronary artery disease (CAD) than people with non fibrotic lung disease or other non-IPF pulmonary fibrosis . Cardiopulmonary exercise test (CPET) is widely employed in patients with heart/lung diseases to study the level of exercise tolerance and to define either preoperative risk for thoracic surgery, or the response to pharmacological therapy and to rehabilitation programmes. For this purpose a cluster of parameters are used [6, 7]: work efficiency (WR, work rate), metabolic response (VO2, oxygen uptake; VCO2, carbon dioxide output; AT, anaerobic threshold), ventilatory/respiratory response (TV, tidal volume; Rf, respiratory frequency; VE, minute ventilation;VE/VCO2 and VE/VO2 ratios, ventilatory equivalents; VD/VT, ratio of physiologic dead space to tidal volume), and cardiovascular response (HR, heart rate; VO2/HR, oxygen-pulse; ΔVO2/ΔWR, change in the oxygen uptake related to the increase in work rate), PaO2, PaCO2, pulmonary gas exchange (arterial oxygen and carbon dioxide partial pressures; SaHbO2, arterial O2 saturation). CPET is rarely of diagnostic use in patients with respiratory or cardiovascular dissease. However, it can aid in the clinical management of patients with established cardiopulmonary diseases.
In this paper we describe a case of IPF and CAD, emphasizing the role of CPET in early diagnosis of CAD.
CPET is a well accepted technique utilized in clinical practice to evaluate cardiovascular and respiratory interactions during physical exercise. It is not routinely used in the management of IPF patients but, when performed, some parameters may have prognostic significance [8, 9]. In addition, although IPF, by definition, is a progressive chronic fibrosing disease limited to the lung, the heart might be involved when gas exchange is so altered that coronary flow is affected. In this context, CPET could be a useful tool to investigate subclinical CAD . While the progression of the underlying lung disease is the most common cause of death for patients with IPF , various studies seem to suggest an additional increase in cardiovascular diseases in this population , which could have an impact on morbidity and mortality. In spite of this, IPF guidelines do not recommend routine screening to evaluate the presence of cardiovascular complications, as it is not clear whether treating comorbidities may influence survival . However, in the context of comprehensive care of IPF patients, an holistic approach was recently proposed , in which identifying and treating comorbidities, such as CAD, could be a strategy to optimize the management of the disease. In the cardiological context, CPET is a well recognized method to diagnose and/or investigate cardiovascular dysfunction (e.g., myocardial ischemia, chronic heart failure) [10, 13]. With respect to lung diseases, the goal of CPET is the identification of physiopathological determinants of respiratory dysfunction as well as matching the pattern of the abnormality with the particular sites of the system involved, thus clarifying the clinical picture and possibly narrowing the differential diagnosis [14, 15]. Furthermore, the physiological link between respiratory and cardiovascular functions might cause the changes in one system to influence the performance of the other. That is, deterioration in gas exchange could be the cause of CAD, which could manifest as changes in the slope of ΔVO2/ΔWR and a flattening of the oxygen-pulse . In previous studies, various indices of exercise capacity have been evaluated as prognostic factors for IPF [9, 17], in particular VO2-max . Moreover, they were shown to be significantly related to prognosis when baseline values and percent variation over time were assessed. Although the results of these investigations were not concordant , due at least partially to the employment of different methodologies, gas exchange impairment during exercise has generally been emphasized as a factor influencing clinical progression of disease in IPF patients.
In our clinical practice, we perform PFTs on IPF patients to monitor progression of the pulmonary disease and to obtain data facilitating its management, such as the optimal time for referral of the patients to a lung transplantation center. Whenever possible, we use CPET to detect early changes in pulmonary physiology, especially gas exchange, and to verify the presence of cardiovascular abnormalities.
We hereby confirm the importance of CPET as a useful procedure to monitor disease progression in IPF patients. CPET can be useful in differentiating whether the worsening of dyspnoea leading to exercise limitation is related to pulmonary or cardiovascular causes. Discriminating between these two possible causes of dyspnoea worsening can be useful in the decision-making process during the management of the patient (e.g., for inclusion in clinical trials and transplantation referral). Furthermore, we stress the necessity of a careful analysis of variables measured for an accurate interpretation of the clinical picture. In particular, we consider that an in-depth study should be started even when slight and/or uncertain responses are obtained from the analysis of involved variables, and even if uncertainties occur in only one of several relevant parameters. In the case described herein, we requested a cardiac workup soon after the time of the initial diagnostic suspicion of CAD. This resulted in an earlier clinical diagnosis and earlier initiation of treatment of the patient.
The conclusion that might be drawn from this report is that a more extensive CPET should be performed for better management of IPF patients, not only with the goal of identifying useful prognostic parameters, but also to detect potentially treatable cardiovascular alterations earlier.
The careful assessment of CPET parameters (e.g., O2 pulse and work efficiency above and below the anaerobic threshold) may not only improve clinical management of IPF patients, but also identify factors predisposing to higher ischemic risk. However, further studies are needed to assess the costs and benefits of associated with generalized use of CPET in the care of IPF patients.
Written informed consent was obtained from the patient for the publication of this report and any accompanying results.
- Raghu G: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011, 183: 788-824. 10.1164/rccm.2009-040GL.View ArticlePubMedGoogle Scholar
- Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KL, Schwartz DA, Noble PW, Raghu G, Brown KK, for the IPF Study Group: The clinical course of patients with idiopathic pulmonary fibrosis. Ann Int Med. 2005, 142: 963-967. 10.7326/0003-4819-142-12_Part_1-200506210-00005.View ArticlePubMedGoogle Scholar
- Daniels CE, Yi ES, Ryu JH: Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J. 2008, 32: 170-174. 10.1183/09031936.00176307.View ArticlePubMedGoogle Scholar
- Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS, Song KS: Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001, 17: 1216-1219. 10.1183/09031936.01.99055301.View ArticlePubMedGoogle Scholar
- Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW: The association between idiopathic pulmonary fibrosis and vascular disease. A population-based study. Am J Respir Crit Care Med. 2008, 178: 1257-1261. 10.1164/rccm.200805-725OC.View ArticlePubMedGoogle Scholar
- ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med. 2003, 167: 211-277.Google Scholar
- Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O’Donnel DE, Puente Maestu L, Schols AM, Singh S, Whipp BJ: Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 2007, 29: 185-209.View ArticlePubMedGoogle Scholar
- King TE, Tooze JA, Scwarz MI, Brown KR, Cherniack : Predicting survival in idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care Med. 2001, 164: 1171-1181. 10.1164/ajrccm.164.7.2003140.View ArticlePubMedGoogle Scholar
- Lama VN, Martinez FJ: Resting and exercise physiology in interstitial lung diseases. Clin Chest Med. 2004, 25: 435-453. 10.1016/j.ccm.2004.05.005.View ArticlePubMedGoogle Scholar
- Belardinelli R, Lacalaprice F, Carle F, Minnucci A, Cianci G, Perna GP, D’Eusanio G: Exercise-induced myocardial ischemia detected by cardiopulmonary exercise testing. Eur Heart J. 2003, 24: 1304-1313. 10.1016/S0195-668X(03)00210-0.View ArticlePubMedGoogle Scholar
- Kizer JR, Zisman DA, Blumenthal MP, Kotloff RM, Kimmel SE, Strieter RM, Arcasoy SM, Ferrari VA, Hansen-Flaschen J: Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004, 164: 551-556. 10.1001/archinte.164.5.551.View ArticlePubMedGoogle Scholar
- Lee JS, Mc Laughlin S, Collard HR: Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2011, 17: 348-354. 10.1097/MCP.0b013e328349721b.View ArticlePubMedGoogle Scholar
- Tajima A, Itoh H, Osada N, Omiya K, Maeda T, Ohkoshi N, Kawara T, Aizawa T, Wasserman K: Oxygen uptake kinetics during and after exercise are useful markers of coronary artery disease in patients with exercise electrocardiography suggesting myocardial ischemia. Circ J. 2009, 73: 1864-1870. 10.1253/circj.CJ-09-0222.View ArticlePubMedGoogle Scholar
- Rodman JR, Haverkamp HC, Gordon SM, Dempsey JA: Cardiovascular and respiratory system responses and limitations to exercise. Clinical Exercise Testing, Volume 32. Edited by: Weisman IM, Zeballos RJ. 2002, Prog Resp Res, 1-17.View ArticleGoogle Scholar
- Ferrazza AM, Martolini D, Valli G: Palange: Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009, 77: 3-17. 10.1159/000186694.View ArticlePubMedGoogle Scholar
- Chaudhry S, Arena R, Wasserman K, Hansen JE, Lewis GD, Myers J, Chronos N, Boden WE: Exercise-induced myocardial ischemia detected by cardiopulmonary exercise testing. Am J Cardiol. 2009, 103: 615-619. 10.1016/j.amjcard.2008.10.034.PubMed CentralView ArticlePubMedGoogle Scholar
- Miki K, Maekura R, Hiraga T, Okuda Y, Okamoto T, Hirotani A, Ogura T: Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med. 2003, 97: 482-490. 10.1053/rmed.2002.1469.View ArticlePubMedGoogle Scholar
- Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR: The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009, 179: 402-407. 10.1164/rccm.200802-241OC.PubMed CentralView ArticlePubMedGoogle Scholar
- Erbes R, Schaberg T, Loddenkemper R: Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome?. Chest. 1997, 111: 51-57. 10.1378/chest.111.1.51.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.